The inhibition of EZH2 upregulates the induction of IFN-stimulated genes in prostate cancer and promotes a marked increase in CD4+ and CD8+ T cells in the TME, reversing the anti-PD-1 therapy resistance of B6-HiMYC PCa transgenic tissue transplant model [120]. The gene discussed is CD8A; the disease is prostate carcinoma.